Surrozen SRZN Stock
Surrozen Price Chart
Surrozen SRZN Financial and Trading Overview
| Surrozen stock price | 24.57 USD |
| Previous Close | 26.21 USD |
| Open | 25.98 USD |
| Bid | 18.36 USD x 200 |
| Ask | 31.65 USD x 200 |
| Day's Range | 24 - 26.83 USD |
| 52 Week Range | 7.8 - 35 USD |
| Volume | 88.35K USD |
| Avg. Volume | 106.09K USD |
| Market Cap | 286.89M USD |
| Beta (5Y Monthly) | 0.589 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -36.59 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.5 USD |
SRZN Valuation Measures
| Enterprise Value | 204.18M USD |
| Trailing P/E | N/A |
| Forward P/E | -6.2007527 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 38.28293 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 27.245 |
| Enterprise Value/EBITDA | -4.783 |
Trading Information
Surrozen Stock Price History
| Beta (5Y Monthly) | 0.589 |
| 52-Week Change | 222.38% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 35 USD |
| 52 Week Low | 7.8 USD |
| 50-Day Moving Average | 28.96 USD |
| 200-Day Moving Average | 20.51 USD |
SRZN Share Statistics
| Avg. Volume (3 month) | 106.09K USD |
| Avg. Daily Volume (10-Days) | 100.16K USD |
| Shares Outstanding | 11.61M |
| Float | 4.75M |
| Short Ratio | 4.86 |
| % Held by Insiders | 3.17% |
| % Held by Institutions | 101.87% |
| Shares Short | 546.22K |
| Short % of Float | 8.55% |
| Short % of Shares Outstanding | 4.70% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -209.11% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -22.81% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 7.49M USD |
| Revenue Per Share (ttm) | 0.81 USD |
| Quarterly Revenue Growth (yoy) | 408.60% |
| Gross Profit (ttm) | -24641000 USD |
| EBITDA | -42689000 USD |
| Net Income Avi to Common (ttm) | -342560992 USD |
| Diluted EPS (ttm) | -36.59 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 106.91M USD |
| Total Cash Per Share (mrq) | 9.21 USD |
| Total Debt (mrq) | 6.78M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 11.913 |
| Book Value Per Share (mrq) | -19.209 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -33460000 USD |
| Levered Free Cash Flow (ttm) | -26107124 USD |
Profile of Surrozen
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 171 Oyster Point Boulevard |
| ZIP | 94080 |
| Phone | 650 489 9000 |
| Website | https://www.surrozen.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 44 |
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Q&A For Surrozen Stock
What is a current SRZN stock price?
Surrozen SRZN stock price today per share is 24.57 USD.
How to purchase Surrozen stock?
You can buy SRZN shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Surrozen?
The stock symbol or ticker of Surrozen is SRZN.
Which industry does the Surrozen company belong to?
The Surrozen industry is Biotechnology.
How many shares does Surrozen have in circulation?
The max supply of Surrozen shares is 11.61M.
What is Surrozen Price to Earnings Ratio (PE Ratio)?
Surrozen PE Ratio is now.
What was Surrozen earnings per share over the trailing 12 months (TTM)?
Surrozen EPS is -36.59 USD over the trailing 12 months.
Which sector does the Surrozen company belong to?
The Surrozen sector is Healthcare.
Surrozen SRZN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}